QuidelOrtho Corporation (LON:0A55)
Market Cap | 1.47B |
Revenue (ttm) | 2.00B |
Net Income (ttm) | -340.09M |
Shares Out | n/a |
EPS (ttm) | -5.04 |
PE Ratio | n/a |
Forward PE | 10.98 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2 |
Average Volume | 177 |
Open | 43.09 |
Previous Close | 43.64 |
Day's Range | 43.09 - 43.50 |
52-Week Range | 29.91 - 69.67 |
Beta | n/a |
RSI | 49.59 |
Earnings Date | Oct 29, 2025 |
About QuidelOrtho
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,... [Read more]
Financial Performance
In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.
Financial numbers in USD Financial StatementsNews

QuidelOrtho to Participate in the Baird 2025 Global Healthcare Conference
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-o...

QuidelOrtho Completes Debt Refinancing
SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-o...

Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities
SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is ...

QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development
SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice Presi...

QuidelOrtho Launches Certified Analyzer Program
Initiative to expand testing access to underserved U.S. communities SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiativ...
QuidelOrtho narrows China outlook to mid-single-digit growth as cost actions drive margin gains

QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Brian J. Blaser - President, CEO & Director Joseph M.
Quidel Non-GAAP EPS of $0.12 beats by $0.11, revenue of $614M beats by $2.12M

QuidelOrtho Reports Second Quarter 2025 Financial Results
― Labs revenue grew 4% as reported and 5% in constant currency ― ― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024...

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™
SAN DIEGO , July 29, 2025 /PRNewswire/ -- QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association for Diagnostics & Laboratory Medicine, reco...

Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast
Episode 49 of QuidelOrtho Science Bytes explores substance use trends, the limits of Narcan, and the evolving challenges facing emergency departments SAN DIEGO , July 24, 2025 /PRNewswire/ -- In emerg...

QuidelOrtho to Report Second Quarter 2025 Financial Results
SAN DIEGO , July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-o...

Real Labs, Actual Decisions With Actionable Six Sigma Metrics
QuidelOrtho Announces Featured ADLM Session SAN DIEGO , July 17, 2025 /PRNewswire/ -- How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagn...

QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)
Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms SAN DIEGO , July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation...

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs
New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO , July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company"...
QuidelOrtho to discontinue Savanna platform development

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics
―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance― ―Company Plans to Discontinue Savanna® Platform Development― ―Company Reaffirms Full Year 2025 Financial Guidance ― ―Company to Hos...

QuidelOrtho to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight
New York, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight The expansion of the preeclampsia diagnostics market is...
SA analyst downgrades: QDEL, AMCX, PLYM, DAY

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
QuidelOrtho's stock jumped after Q1 2025 earnings beat, but long-term growth remains weak. Check out why QDEL stock is downgraded to hold.
Quidelortho sees $30M-$40M tariff impact offset, maintains 2025 guidance

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and C...

QuidelOrtho Reports First Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...

QuidelOrtho to Report First Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setti...